Clinical Trials Browser

Phase 2 × Breast Neoplasms × Pharmaceutical Preparations × Clear all

NCT06207734 2025-05-01

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms